3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
41
Stomach Neoplasms
2
Neoplasm Metastasis
2
HER2-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Solid Tumors
1
Recurrence
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Inflammatory Breast Neoplasms
1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
1
HER2-Positive Primary Breast Cancer
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Cancer Metastatic
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
40
Gemcitabine
37
Cisplatin
28
Carboplatin
17
enfortumab vedotin
15
Nivolumab
15
Mitomycin
14
atezolizumab
13
avelumab
12
Docetaxel
10
vinflunine
9
5-aminolevulinic acid hexyl ester
9
apaziquone
8
Paclitaxel
8
BCG Vaccine
7
durvalumab
6
Fluorouracil
6
Cystectomy
6
sacituzumab govitecan
4
Surgical Procedures, Operative
4
Drug Therapy
4
vofatamab
3
valrubicin
3
tisotumab vedotin
3
erdafitinib
3
cemiplimab
3
belinostat
3
Therapeutic Uses
3
Ramucirumab
3
Cystoscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urinary Bladder Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT02999672
2019-08-28
KAMELEON
Hoffmann-La Roche
Phase 2
Completed
20 enrolled
14 charts